Download biomedica product list
Cardiac Biomarkers - kits for clinical & preclinical use
The natriuretic peptides NT-proBNP & NT-proANP
Cardiac Biomarkers – kits for clinical & preclinical use
NT-proBNP is released in the heart in response to cardiac wall stretch or pressure overload. It is considered as the gold standard in heart failure and is useful for both diagnosis and prognosis (1).
NT-proANP is synthesized and stored in atrial myocytes in response to increased intra-atrial pressure. Elevated circulating levels of NT-proANP are associated with heart failure resulting from increased mechanical stress in the heart during hypertension. In population-based studies, elevated plasma NT-pro-ANP levels predicted the risk of cardiovascular events and death ( 2).
Cardiac Biomarkers – kits for clinical & preclinical use
Natriuretic peptides in pre-clinical models as cardiac toxicity biomarkers
Biomarkers are also a valuable tool to explore drug effects in pre-clinical models. The natriuretic peptide NT-proANP has successfully been validated as a cardiovascular safety biomarker in rodents (3). An additional cardiac toxicity biomarker in drug development is NT-proBNP supporting the use of natriuretic peptides to investigate drug-induced cardiac hypertrophy (4, 5).
Biomedica offers a range of top quality ELISA kits for your clinical & preclinical research
- NT-proBNP – human (CE-marked in EU) (#SK-1204)
- NT-proBNP – rat (new!) (#BI-1204R)
- NT-proANP – human, rodent (#BI-20892) citations rat/mouse
Reliable ELISA kits for your research
- widely cited in over 400 publications
- kit validation follows international quality guidelines
LITERATURE
- NT-proBNP: The Gold Standard Biomarker in Heart Failure. McKie PM, Burnett JC Jr. J Am Coll Cardiol. 2016; 6;68(22):2437-2439.
- Plasma natriuretic peptide levels and the risk of cardiovascular events and death. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. N Engl J Med. 2004; 12;350(7):655-63.
- Cross-laboratory analytical validation of the cardiac biomarker NT-proANP in rat. Vinken P, Reagan WJ, Rodriguez LA, Buck WR, Lai-Zhang J, Goeminne N, Barbacci G, Liu R, King NM, Engle SK, Colton H. Pharmacol Toxicol Methods. 2016; 77:58-65.
- Evaluation of Cardiac Toxicity Biomarkers in Rats from Different Laboratories. Kim K, Chini N, Fairchild DG, Engle SK, Reagan WJ, Summers SD, Mirsalis JC – Cardiac Hypertrophy Working Group of the Predictive Safety Testing Consortium. Toxicol Pathol. 2016; 44(8):1072-1083.
- Serum Natriuretic Peptides as Differential Biomarkers Allowing for the Distinction between Physiologic and Pathologic Left Ventricular Hypertrophy. Dunn ME, Manfredi TG, Agostinucci K, Engle SK, Powe J, King NM, Rodriguez LA, Gropp KE, Gallacher M, Vetter FJ, More V, Shimpi P, Serra D, Colton HM – Cardiac Hypertrophy Working Group of the Predictive Safety Testing Consortium. Toxicol Pathol. 2017; 45(2):344-352.
For use in preclinical models – cardiotoxicity biomarkers
Rat NT-proBNP ELISA , cat. no. BI-1204R
NT-proANP ELISA independently validated for rat, cat. no. BI-20892